ATE311198T1 - Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor - Google Patents

Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor

Info

Publication number
ATE311198T1
ATE311198T1 AT01931460T AT01931460T ATE311198T1 AT E311198 T1 ATE311198 T1 AT E311198T1 AT 01931460 T AT01931460 T AT 01931460T AT 01931460 T AT01931460 T AT 01931460T AT E311198 T1 ATE311198 T1 AT E311198T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
factor viia
tfpi inhibitor
tfpi
Prior art date
Application number
AT01931460T
Other languages
English (en)
Inventor
Marianne Kjalke
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of ATE311198T1 publication Critical patent/ATE311198T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT01931460T 2000-05-10 2001-05-10 Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor ATE311198T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000778 2000-05-10
DKPA200000771 2000-05-10
DKPA200000871 2000-06-06
PCT/DK2001/000324 WO2001085199A1 (en) 2000-05-10 2001-05-10 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR

Publications (1)

Publication Number Publication Date
ATE311198T1 true ATE311198T1 (de) 2005-12-15

Family

ID=27222387

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01931460T ATE311198T1 (de) 2000-05-10 2001-05-10 Pharmazeutische zusammensetzung enthaltend einen faktor viia und einen tfpi-inhibitor
AT01931458T ATE300953T1 (de) 2000-05-10 2001-05-10 Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01931458T ATE300953T1 (de) 2000-05-10 2001-05-10 Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen

Country Status (17)

Country Link
US (3) US20030092627A1 (de)
EP (3) EP1282439B1 (de)
JP (2) JP2003532684A (de)
CN (1) CN1304049C (de)
AT (2) ATE311198T1 (de)
AU (3) AU2001258230A1 (de)
BR (1) BR0110659A (de)
CA (1) CA2406583A1 (de)
CZ (1) CZ20023667A3 (de)
DE (2) DE60112429T2 (de)
DK (1) DK1282438T3 (de)
ES (2) ES2247106T3 (de)
HU (1) HUP0301868A3 (de)
IL (1) IL152554A0 (de)
NO (1) NO20025355L (de)
PL (1) PL365042A1 (de)
WO (2) WO2001085199A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ305123B6 (cs) * 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP2226385B1 (de) * 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Varianten des menschlichen Koagulationsfaktors VII
RU2326126C2 (ru) 2000-09-13 2008-06-10 Ново Нордиск Хелт Кэр Аг Полипептид фактора vii свертывания крови, его получение и применение
WO2002036155A1 (en) * 2000-11-03 2002-05-10 Zymogenetics, Inc. Use of blood coagulation factor xiii for treating haemophilia a
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
ES2288524T3 (es) * 2000-11-10 2008-01-16 Zymogenetics, Inc. Factor xiii en combinacion con factor ix para tratar la hemofilia b.
CA2437015A1 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
EP1379271A1 (de) * 2001-02-21 2004-01-14 ZymoGenetics, Inc. Therapie des von willebrand syndroms
EP1425034A4 (de) * 2001-09-10 2005-09-21 Zymogenetics Inc Verfahren zur behandlung von durch cumarin induzierten blutungen
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Vii因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
EP1446147A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmazeutische zusammensetzung, die faktor vii polypeptide und tranexamsäure enthält
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第vii因子ポリペプチドの液体組成物
KR101006070B1 (ko) * 2001-12-21 2011-01-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 액체 조성물
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ES2321297T3 (es) * 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular.
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
EP1656158B1 (de) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Flüssige, wässrige pharmazeutische zusammensetzung von faktor-vii-polypeptiden
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
JP2008510476A (ja) * 2004-08-27 2008-04-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 生物学的材料からのxiii因子ポリペプチドの精製
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
US8461302B2 (en) 2004-11-23 2013-06-11 Zymogenetics, Inc. Purification of recombinant human factor XIII
JP5236952B2 (ja) * 2005-02-28 2013-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 改善された特性を有するfxiiiバリアント
WO2007014749A2 (en) * 2005-07-29 2007-02-08 Universiteit Van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
DK2004214T3 (da) * 2006-03-16 2013-02-18 Stellaris Pharmaceuticals Aps Lokalbehandling med faktor VII
WO2008009635A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
RU2571931C2 (ru) * 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子vii多肽和其用途
WO2009130181A2 (en) 2008-04-21 2009-10-29 Novo Nordisk Health Care Ag Dry transglutaminase composition
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2379096B1 (de) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi-inhibitoren und anwendungsverfahren
ES2983470T3 (es) * 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
AU2011287360A1 (en) * 2010-08-05 2013-02-21 Council Of Scientific & Industrial Research Protein fusion constructs possessing thrombolytic and anticoagulant properties
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
US20210263052A1 (en) * 2018-07-25 2021-08-26 Sony Corporation Blood coagulation system analysis device
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
EP3833381B1 (de) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
ATE66374T1 (de) * 1985-11-26 1991-09-15 Novo Nordisk As Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
AU2793292A (en) * 1991-10-11 1993-05-03 Novo Nordisk A/S Hemostatic composition for local hemostasis
EP0624095B2 (de) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Verfahren und zusammensetzungen zur verminderung von blutverlust
EP0651655A4 (de) * 1992-07-24 1996-05-29 Oklahoma Med Res Found Blockierung der protein c aktivierung reduziert den blutverlust in mikrogefässen bei chirurgischen eingriffen.
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
WO1997029792A1 (en) * 1996-02-20 1997-08-21 Cohesion Corporation Tissue sealant compositions and methods of use thereof
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
AU2094199A (en) * 1997-12-23 1999-07-12 Nuvas Llc Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium
EP1076698A2 (de) * 1998-05-14 2001-02-21 Battelle Memorial Institute Menschliche blutgerinnungsfaktoren aus transgenen pflanzen
EP1148427A1 (de) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Methode und System zur Erzeugung eines Lesezeichen-Knopfs in einem Web-Browser mit der Darstellung eines vom Benutzer ausgewählten Teils der zugehörigen Datei
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
CA2437015A1 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Vii因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第vii因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides

Also Published As

Publication number Publication date
EP1282439A1 (de) 2003-02-12
NO20025355D0 (no) 2002-11-08
NO20025355L (no) 2003-01-09
EP1282439B1 (de) 2005-11-30
WO2001085198A1 (en) 2001-11-15
CN1304049C (zh) 2007-03-14
CN1429117A (zh) 2003-07-09
CA2406583A1 (en) 2001-11-15
HUP0301868A3 (en) 2006-11-28
WO2001085199A1 (en) 2001-11-15
ES2254414T3 (es) 2006-06-16
EP1282438A1 (de) 2003-02-12
AU5822801A (en) 2001-11-20
IL152554A0 (en) 2003-05-29
EP1282438B1 (de) 2005-08-03
HUP0301868A2 (hu) 2003-08-28
JP2003532684A (ja) 2003-11-05
AU2001258228B2 (en) 2006-01-12
ATE300953T1 (de) 2005-08-15
PL365042A1 (en) 2004-12-27
DE60115422T2 (de) 2006-08-17
CZ20023667A3 (cs) 2003-04-16
DE60112429T2 (de) 2006-06-01
DE60115422D1 (de) 2006-01-05
AU2001258230A1 (en) 2001-11-20
US20030092627A1 (en) 2003-05-15
ES2247106T3 (es) 2006-03-01
DE60112429D1 (de) 2005-09-08
DK1282438T3 (da) 2005-11-14
US20070280920A1 (en) 2007-12-06
BR0110659A (pt) 2003-02-11
US20060199766A1 (en) 2006-09-07
JP2004505016A (ja) 2004-02-19
EP1593389A1 (de) 2005-11-09

Similar Documents

Publication Publication Date Title
DE60115422D1 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR
SE0102315D0 (sv) Compounds
ATE380054T1 (de) Topisches mittel zur dermatologischen verwendung enthaltend 4-hydroxyphenyl-alpha-d-glucopyranosid
AR027968A1 (es) Una composicion para utilizar en el tratamiento y/o prevencion del sarampion y el uso de dicha composicion para un vehiculo para el tratamiento o prevencion del sarampion
FI961863A0 (fi) Farmaseuttinen seos, joka sisältää ACE-inhibiittorin ramipriilin ja dihydropyridiiniyhdisteen
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
IT1309427B1 (it) Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
MX9306079A (es) Agente inmunopotenciador y sus sales fisiologicamente aceptables.
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
ATE302746T1 (de) Amorphe salpetersäureester und deren pharmazeutische zusammensetzungen
FI935172A7 (fi) Katepsiini G:n ja elastaasin inhibiittoreita sidekudoksen rappeutumise n ehkäisemistä varten
IL145684A0 (en) Treatment of pulmonary hypertension
ATE315395T1 (de) Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
IT1318556B1 (it) Composizione farmaceutica a base di prolina, glicina e lisina utilenella terapia per la cicatrizzazione delle ferite e delle lesioni
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
DE60216979D1 (de) Synergistische zusammensetzung aus trans-tetracos-15-ensäure und apocynin, und verwendung davon
BR8000753U (pt) Balão de inflar para decoração e folguedos
FI20001580A7 (fi) Hypnoosikasetti: "psyykkinen työ"
ATE314073T1 (de) Kombination von aktiva mit alfuzosin und apomorphin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties